Related Experiment Video
Updated: Dec 27, 2025
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
PKCα and Netrin-1/UNC5B positive feedback control in relation with chemical therapy in bladder cancer
1Department of Urology, The First Affiliated Hospital of China Medical University, Shenyang, China. mskongchuize@sina.com.
Objective:
To explore the cisplatin medical tolerance mechanism affecting bladder cancer cells.
Materials And Methods:
Bladder cancer cells were treated with protein kinase C α (PKCα) stimulation and inhibition agents. The small-interfering RNA (siRNA) inhibitory technique was used to differentiate and remove Netrin-1 from UNC5B. Cells treated by cisplatin were processed by the MIT method to estimate cell death and growth rate. The Western blot method was utilized to analyze PKCα, netrin-1, and UNC5B in bladder cancer cells, used in the relative control sample. Co-immunoprecipitation was employed to analyze PKCα, netrin-1, and UNC5B combination effects.
Results:
PKCα high activity, netrin-1 high expression, and UNC5B with low expression can enhance bladder cancer cells cisplatin medical tolerance. PKCα low activity, netrin-1 low expression, and UNC5B with high expression can also enhance bladder cancer cells sensitivity to chemical therapeutic treatments. PKCα high activity with enhanced netrin-1 reduced UNC5B expression, and also enhanced netrin-1/UNC5B combination. It inhibits and/or deletes PKCα, Netrin-1 lower stream extracellular regulated protein kinases (ERK) signal, deletes UNC5B, PKCα, and lowers stream (ERK) signaling from activity.
Conclusions:
PKCα and netrin-1/UNC5B form a positive feedback control loop in relation to the regulation of cisplatin in bladder cancer cells.
Insights
Protein kinase C alpha (PKCα) and netrin-1/UNC5B signaling influence bladder cancer cell tolerance to cisplatin. Understanding this feedback loop can improve chemotherapy effectiveness.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Cisplatin is a cornerstone chemotherapy for bladder cancer.
- Mechanisms of cisplatin resistance in bladder cancer cells remain incompletely understood.
- Targeting specific molecular pathways may overcome therapeutic resistance.
Purpose of the Study:
- To investigate the role of protein kinase C alpha (PKCα) and the netrin-1/UNC5B axis in modulating bladder cancer cell response to cisplatin.
- To elucidate the molecular mechanisms underlying cisplatin resistance.
Main Methods:
- Bladder cancer cells were treated with PKCα modulators and netrin-1/UNC5B targeting agents.
- Cell viability and growth were assessed using the MIT method.
- Protein expression and interactions were analyzed via Western blot and co-immunoprecipitation.
- Small-interfering RNA (siRNA) was used to modulate gene expression.
Main Results:
- High PKCα activity, elevated netrin-1, and low UNC5B expression correlated with increased cisplatin tolerance.
- Conversely, low PKCα activity, reduced netrin-1, and high UNC5B expression enhanced sensitivity to cisplatin.
- PKCα and netrin-1 positively regulate each other, impacting UNC5B expression and downstream ERK signaling.
Conclusions:
- PKCα and the netrin-1/UNC5B pathway form a positive feedback loop that regulates cisplatin resistance in bladder cancer.
- This feedback loop represents a potential therapeutic target for overcoming cisplatin resistance.
Related Concept Videos
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
01:15Drugs that Stabilize Microtubules
02:38Mitogens and the Cell Cycle